For instance, three drugs including Palbociclib, Ribociclib, and Abemaciclib are selective CDK4/6 inhibitors and are used for treating HER2+/HR advanced breast cancer and have been approved by the FDA in 20174. The gene discussed is CDK4; the disease is breast carcinoma.